Research
Hormonal
Exenatide reduces hunger scores in adults with craniopharyngioma-related obesity, although this does not translate to significant weight loss.
Exenatide may help reduce the subjective feeling of hunger in patients with craniopharyngioma-related obesity, but this reduction in hunger does not necessarily lead to greater weight loss compared to lifestyle interventions alone.
GoodQualifiesHIGH confidence
Results were compatible with a higher reduction of hunger score with exenatide compared with placebo (estimated treatment difference in change from baseline to week 26: −2.3, 95% CI −4.5 to −0.2)
Why this rating
Statistically significant secondary outcome in a well-designed RCT.
Source
Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial
Blandine Gatta‐Cherifi et al. · European Journal of Endocrinology · 2024
DOI 10.1093/ejendo/lvae024
rct · n=41Cited 21×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →